Prognostic factors for clinical outcomes of patients with central nervous system leukemia

Patients with CNS leukemia treated with intrathecal chemotherapy alone had significantly better 3-year overall survival compared to those who received intrathecal chemotherapy in combination with cran

Effect: improvement; 51% vs. 18%

Patients with CNS leukemia who received intrathecal consolidation chemotherapy after achieving CNS complete remission had significantly improved 3-year overall survival in a dose-dependent pattern com

Effect: improvement; 61% vs. 53% vs. 13%

Patients who achieved systemic leukemia complete remission had a significantly higher probability of achieving CNS leukemia complete remission compared to those who did not achieve systemic remission.

Effect: improvement; 89% vs. 58%

Patients who developed CNS leukemia after hematopoietic cell transplantation had uniformly fatal outcomes, with 0% 3-year survival, compared to patients diagnosed with CNS leukemia before or at the ti

Effect: decline; 0% vs. 42% vs. 47%

Pediatric patients with CNS leukemia had significantly better 3-year overall survival compared to adult patients, though the likelihood of achieving CNS complete remission was not significantly differ

Effect: decline; 81% vs. 28%

Patients who achieved and maintained CNS leukemia complete remission had the best 3-year survival at 60%, those with CNS relapse had 30% survival, and none of the patients with persistent CNS leukemia

Effect: improvement; 60% vs. 30% vs. 0%